Zymeworks Inc. (ZYME) is a publicly traded company in the Unknown sector. Across all available filings, 18 corporate insiders have executed 152 transactions totaling $76.3M, demonstrating a bullish sentiment with $23.6M in net insider flow. The most recent transaction on Jan 12, 2026 involved a transaction of 17,666 shares valued at $0.
No significant insider buying has been recorded for ZYME in the recent period.
No significant insider selling has been recorded for ZYME in the recent period.
Based on recent SEC filings, insider sentiment for ZYME is bullish with an Insider Alignment Score of 65/100 and a net flow of $23.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Zymeworks Inc. (ZYME) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 18 insiders are actively trading ZYME stock, having executed 152 transactions in the past 90 days. The most active insider is Capital, Llc Ecor1 (Executive), who has made 9 transactions totaling $49.4M.
Get notified when executives and directors at ZYME file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | T. L. Smith Jeffrey | EVP & Chief Medical Officer | Option Exercise | 17,666 | $N/A | $0 | |
| Jan 12, 2026 | T. L. Smith Jeffrey | EVP & Chief Medical Officer | Sale | 9,310 | $22.67 | $211.1K | |
| Jan 12, 2026 | T. L. Smith Jeffrey | EVP & Chief Medical Officer | Option Exercise | 17,666 | $N/A | $0 | |
| Jan 6, 2026 | D. Patterson Leone | EVP, Chief Bus & Fin Officer | Award | 459 | $10.55 | $4.8K | |
| Jan 5, 2026 | T. L. Smith Jeffrey | EVP & Chief Medical Officer | Option Exercise | 20,000 | $N/A | $0 | |
| Jan 5, 2026 | T. L. Smith Jeffrey | EVP & Chief Medical Officer | Sale | 10,538 | $25.10 | $264.5K | |
| Jan 5, 2026 | T. L. Smith Jeffrey | EVP & Chief Medical Officer | Option Exercise | 20,000 | $N/A | $0 | |
| Dec 22, 2025 | Galbraith Kenneth | Executive | Option Exercise | 100,000 | $N/A | $0 | |
| Dec 22, 2025 | Galbraith Kenneth | Executive | Sale | 47,528 | $27.02 | $1.3M | Large |
| Aug 12, 2025 | Austin Ciongoli Gregory | Executive | Award | 415,000 | $12.02 | $5.0M | Large |
| Jan 8, 2024 | Andrew Moore Paul | Executive | Sale | 2,339 | $11.22 | $26.2K | |
| Jan 8, 2024 | Astle Christopher | Executive | Sale | 1,431 | $11.22 | $16.1K | |
| Jan 8, 2024 | Galbraith Kenneth | Executive | Sale | 5,706 | $11.22 | $64.0K | |
| Jan 5, 2024 | Andrew Moore Paul | Executive | Sale | 7,460 | $10.65 | $79.4K | |
| Jan 5, 2024 | Andrew Moore Paul | Executive | Option Exercise | 17,166 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 15 | $49.9M | 59.7% |
Sale(S) | 57 | $26.3M | 31.5% |
Award(A) | 28 | $5.4M | 6.4% |
Exercise(M) | 52 | $2.1M | 2.5% |
Insiders at Zymeworks Inc. are accumulating shares at an accelerated pace. With 18 insiders making 152 transactions totaling $49.9M in purchases versus $26.3M in sales, the net buying activity of $23.6M signals strong executive confidence. Capital, Llc Ecor1 (Executive) leads the buying activity with $49.4M in transactions across all time.